{"ticker": {"uuid": "2a0cec4d-a704-4ae1-bd50-3e444a6dc20d", "symbol": "APLM", "name": "Apollomics Inc. Class A Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Apollomics Inc. (APLM) appoints Hung-Hsien Yen to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQc1pxd2x4cnBvN2NveURRbmF4LTRLNGp1QjRJZ0xKZUVfdDc1aTJ5c0VyQzRvVFZzUnYxeUJfMmNFZHVTNmxBbHY4Y25jRlRtUnNZWkVTZkxiSl9sSEROeFpSUGswdHVnQlVMU3d2d2l6cUVrMDJHWUsyUWVYYkk1a05BSi1VblhfUUVBMTk3OWRFa0QwT3VoWGZ1cDRJemtrWndERGFOVURjcTEyYS1z?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T19:13:53+00:00", "published_display": "21 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Plunges Over 21%: Key Support Levels Tested Amid Heavy Selling - IV Rank", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNWVF0bWFQaERNODBJY3Fvd29pRmhmbXdiLUlBOTNKOTNNR1dXSnJxQ0p4TFlQNGxYYVJGNUp4TzZ5a0Rjd0QtdXJBQlFjNjBtSTNURW1ERHpyRUlnUFJFWEtCV1FqWmNRbmVPV0wxdHpldDdOeUpBMkFWTFBiTVBUelIxc3B0OHo4SkFFN1hyX2NJTmhjeXB1U0lzYjRRWXRZVXFaakdsOXFzWFU4aVBmc0JtNkdrZjNOay1XbDlsZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-17T19:31:10+00:00", "published_display": "17 Jul 2026 19:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Apollomics (Nasdaq: APLM) restores compliance with Nasdaq $35M MVLS rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOeHZrc1g1XzR5YXRaUmMxVzRORjJOZ0d2blM2MW8ydlpiUXV2Rlh3eEE4TnljVjN3b0ROWFZ2cW1MWGlfWndwcFZtN1VEUkk2a1NTd0VoU2l5VXFYM1VMYUlidUlSZjlQT2hUWEZmN2tFN2d6OTVFbmlVS1h2UE13UjJkWGZLMDFDX3hvb2prVXR0UmtQT3hRNDNZNUFSbk1uTXdyZGNnTEFIUkhla3Vj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Regains Full Compliance with Nasdaq Listing Requirements", "summary": "Apollomics Inc., a biopharmaceutical company, announced it has regained full compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement. The company had previously received notice of non-compliance but has since maintained the required $35 million MVLS for 10 c", "url": "https://www.sahmcapital.com/news/content/apollomics-regains-full-compliance-with-nasdaq-listing-requirements-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T01:12:20", "published_display": "14 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq restores Apollomics listing compliance after MVLS climbs back to $35M", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOTzJGbDBBZ2x2eHZMQ3I4WC1sdm82T2lDelR3Q01HWXhVX1Fna1lVd3ZKMWRJZnVkX1NJVGZuSUk0VG9xTnhCU2QxWDJYeG1HMVhqNDI0SVpoZ1lrSUt5NFc3bmwyNzJzNHRKUGZveTBSVHFnd3pQcUpxdGRNMFpiRGg5ZElJNkVZYy1tOFh3WVpobFNEbTNJV19NREhHV2JtRHpIUXhaNFQwMDZta2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Apollomics Inc. (APLM) Plunges Over 10%, Testing Key Support at $18.14 - Dynamic Hedging", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNT1B6LVhwc25vamdlbG9zeDZzTVc3VXU1bVdLQjdYbFVjbzVBUWJmZzRESktwcVhWSmpqSThrMmxya2hmeXpLTlctMjVsdFE3N0Q5RnF6bFZ0QkttX0xyOE9ESVQ1dUNua3JtQUJQZ3JtRzhlM3ZrSk15c29XbE5sRmNoYXZtX2JnVGVCRGJaa0tmZ05PSVVibE5mQ2FzcjdEWnZXSQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. Class A Actuals & Estimates (BOATS:APLM)", "summary": "This article provides an overview of Apollomics Inc. (APLM) stock, including its ticker information, analyst forecasts, historical price performance, and financial data. It explains where to find financial reports, its next earnings date, net income, dividend policy, and employee", "url": "https://www.tradingview.com/symbols/BOATS-APLM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:26", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Receives Nasdaq Deficiency Notice Over Market Value Requirement", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/apollomics-receives-nasdaq-deficiency-notice-205209617.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:52:09+00:00", "published_display": "24 Jun 2026 20:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/apollomics-receives-nasdaq-deficiency-notice-201500175.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T20:15:00+00:00", "published_display": "24 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Receives Nasdaq Deficiency Notice Regarding", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxNa0llMjlOd0VFMGN3cWIycUVnSEJfeTg1OTk1NkZhQS1UNDVHdVVSZ2dJZlN2c3NJTURxMVFyeTNuRjN6SFMxSVhfdTRxWG9oemNhWjlsTHNkM3RoQTBQb1dUc09rQWtUVFZHZEpjYUd5RG16T1l6UTZQNkJvUXhzaHdxQ0E3R2FFUzhYY1EtTDloOGNYV2ZXaXVNblppRWdHbWp6VmFLNHpRdXRHME5xR0Y2bktXeDFwWFloTV83X2lucnlmMkV1T1pJSnhnSVBFYTNZUnd4VjZMbW1vVzVCcGpDSl9TNXdjY2wwUU9LWHdVZ1dPRkFKUVduOVk0NHowWFBYcVNxUzljb0dvUng1WDZmelZ6SkkxS01NQ2VTbmZuVllzLTdDWm1DNmlDQ0FhSFZKcg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq flags Apollomics (NASDAQ: APLM) as MVLS falls short and Launxp deal ends", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNZ1gwRHhSS0VmWXBET0NDT2wxUHZqbm5RU2NSSDdGcEw2X1k1eENFNXBPdmZ0Tll1c3ZXSTVoQVk4U0l6U0VnWU10TkZpZzVxTkFWM3U3b19vU1JFQlJkVFB0UGJ0ZnZJNmdXazZnOVFQSkZvVTlyMTdQZHRUbW1uLUtBaEdvQWhiUGpYTFhaWjNvZVQyQ3pzajJiMXh6aGhmVDgzaEM2TE96NGdhY3dz?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CFO RSU vesting triggers 3,588-share tax withholding", "summary": "Apollomics Inc. (APLM) CFO Peter Kuan-How Lin reported the vesting of 10,000 Restricted Stock Units (RSUs) on June 15, 2026, which converted into Class A Ordinary Shares. To cover tax obligations related to this vesting, 3,588 shares were disposed of through a tax-withholding mec", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-87654a8ca2e9.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:39:55", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CEO Hung-Wen Chen gains 5,000 shares as RSUs vest", "summary": "Apollomics Inc. CEO Hung-Wen Chen acquired 5,000 Class A Ordinary Shares due to the vesting of Restricted Stock Units on June 15, 2026. This transaction was not an open-market trade but an equity compensation event, with shares valued at $0.00 each. Following this, Chen directly ", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-8fbeeddff6dc.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:10:22", "published_display": "17 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director receives 500 shares from RSU vesting", "summary": "Apollomics Inc. director Tsai Hsien-Shu increased his direct equity stake by 500 Class A Ordinary Shares due to the vesting of 500 Restricted Stock Units (RSUs) on June 15, 2026. This transaction is part of a pre-scheduled equity compensation plan, with additional RSUs set to ves", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-98b503af032b.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:05:22", "published_display": "17 Jun 2026 02:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Apollomics Inc. Insider Trading Activity", "summary": "Apollomics Inc.'s COO, Yi-Kuei Chen, reported insider trading activity involving restricted stock units (RSUs). On June 15, 2026, he exercised 5,000 RSUs, receiving Class A Ordinary Shares, increasing his direct holdings to 15,000 shares. He also has an indirect interest in over ", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-2d2ac5bdf8d7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director vests 500 RSUs into Class A shares", "summary": "Apollomics Inc. director Hong-Jung Chen converted 500 Restricted Stock Units (RSUs) into 500 Class A Ordinary Shares on June 15, 2026, at an exercise price of $0.00 per share. This transaction increased his direct holdings to 3,620 Class A Ordinary Shares. This vesting event was ", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-14b5ba6469a8.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Apollomics (APLM) gains 500 shares from vested RSUs", "summary": "Apollomics Inc. director Jan Chen-Huan reported a routine equity compensation event where 500 Restricted Stock Units (RSUs) vested into 500 Class A Ordinary Shares on June 15, 2026. Following this transaction, Chen-Huan directly holds 1,500 Class A Ordinary Shares and 500 RSUs. T", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-2fba81a1dda4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director acquires 500 shares through RSU vesting", "summary": "Apollomics Inc. director, CHU YI-AN, acquired 500 Class A Ordinary Shares through the vesting and exercise of Restricted Stock Units (RSUs) at a price of $0.00 per share. This transaction, which occurred on June 15, 2026, increased CHU YI-AN's direct holdings to 1,500 Class A Ord", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-129aaeefb09c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Faces Pressure Amid Recent Decline \u2013 Key Levels to Watch - PCR Extreme", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPenhVS2FLb0dteWdZWDFsUE1WR2VNb3I3V2NHMXVVNWFjUnNWT01vcWlFaGt5SV85ekM4cmV1T3RSbXZ1ZERodnZMamNkMWhDVS1BOGJrZUExblFLbWxBMlcxaGxLTlRCUmQzcjJoV1hVcFFEd2I5aXhDa29KbWZYTFR6dTZYd2dvdHlrVk55R1dXUEJLRmRKQlVRX3dCOXo5dlBjMFJqS0RQeWZVdVJ1bFpBSjZwVTZ6NExF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Edges Higher as Stock Tests Resistance Near $14.86 - Pre-Earnings Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOeFNNZVR0NHNRa2dlTGdfZ3pQQmpBekoycEVmcjZ6LUxxU0d2ZWIzN0J3NnhQYUYyZGt1cl9JY3BQam5YS1pEZlhDR2JCdDI1MVlEN3QxWGs3MjZ6Yzc5WnZYenV5TENnSE8wSWpLbnRNa0NjUElXTXhqb0pGckM4dTJQWWFLd3I1dWFQRG5keWVlUllHbnNNSkUxaTMzOXdLejI5NG0ySEJfMkJSSEJ0ZkVB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Holds Steady Near Support Level as Consolidation Persists - ETF Premium Discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNU2sxRnpVWXVfVUs3RWcxeUh5UFBxMHJTbXZtX0Z1aHk5ZGJDQkxWZzNQc3FIbHFTT3dSWGJ3bFZHaVJjOFJfcW9LU3ZEa0ZwbVRHWDQzN3lycC1WNWo4MmpQSTBiNVRZM2FjTy1POU9IamNLd1h4Qmc3T0dOMW82R3A0NDAwWmNfNHhqVFpNVnBTRWhodnRrNWx1aWFDU1o0Zm5Nd3dqd3JNazgzTVNtenFqWkJNLUpwMGVGdnF3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (Nasdaq:APLM) - Stock Analysis", "summary": "Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on oncology therapies, with a market capitalization of US$32.9 million. The company faces significant risks including negative shareholder equity, substantial share dilution, and volatile share p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aplm/apollomics", "source_name": "Simply Wall Street", "published_at": "2026-05-19T14:08:54", "published_display": "19 May 2026 14:08", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) files F-3/A to register 279,775 Class A shares", "summary": "Apollomics Inc. has filed an F-3/A amendment to register 279,775 Class A ordinary shares for resale by existing securityholders who acquired them through PIPE subscription agreements. This registration is to satisfy certain registration rights, and Apollomics will not receive any", "url": "https://www.stocktitan.net/sec-filings/APLM/f-3-a-apollomics-inc-amended-foreign-issuer-shelf-registration-36fec23c9164.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:39:09", "published_display": "15 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "APLMW | Apollomics Inc. Warrant Insider Trading", "summary": "This article provides an overview of Apollomics Inc. Warrant (APLMW) with a focus on potential insider trading activity, institutional holdings, and other financial data. It notes that there is no recent insider trading data or Congress trading data for this ticker. The piece als", "url": "https://www.quiverquant.com/stock/APLMW/insiders/", "source_name": "Quiver Quantitative", "published_at": "2026-05-02T20:39:51", "published_display": "02 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress", "summary": "Apollomics Inc. announced its full-year 2025 financial results, highlighting a strategic turnaround and significant progress in its clinical pipeline. The company is actively advancing vebreltinib, a c-MET inhibitor, with ongoing Phase 2 studies and plans for an IND submission fo", "url": "https://www.manilatimes.net/2026/04/27/tmt-newswire/globenewswire/apollomics-reports-full-year-2025-financial-results-and-provides-clinical-updates-and-business-progress/2329261", "source_name": "The Manila Times", "published_at": "2026-04-30T21:09:43", "published_display": "30 Apr 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Over 282 subjects enrolled as Apollomics targets 2027 U.S. filing", "summary": "Apollomics (Nasdaq: APLM) reported full-year 2025 financial results, with revenue reaching $8.5 million and net loss narrowing to $10.9 million. The company is advancing the global development of its lead oncology asset, vebreltinib (APL-101), with over 282 subjects enrolled in t", "url": "https://www.stocktitan.net/news/APLM/apollomics-reports-full-year-2025-financial-results-and-provides-5ee6bul16siu.html", "source_name": "Stock Titan", "published_at": "2026-04-30T02:39:19", "published_display": "30 Apr 2026 02:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "APLM SEC Filings - APOLLOMICS INC 10-K, 10-Q, 8-K Forms", "summary": "This page on Stock Titan provides a comprehensive resource for Apollomics Inc. (APLM) SEC filings, including annual reports (10-K, 20-F), quarterly earnings (10-Q), material events (8-K, 6-K), and insider trading forms. It offers direct access to regulatory disclosures as Apollom", "url": "https://www.stocktitan.net/sec-filings/APLM/page-3.html", "source_name": "Stock Titan", "published_at": "2026-04-24T18:39:28", "published_display": "24 Apr 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Apollomics (APLM) CFO has shares withheld for RSU tax obligations", "summary": "Apollomics Inc.'s Chief Financial Officer, Peter Kuan-How Lin, had 3,582 Class A Ordinary Shares withheld to cover tax obligations at $15.85 per share upon the vesting of restricted stock units (RSUs). This was a routine tax-withholding event, not an open-market sale. Following t", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-dad9b6707276.html", "source_name": "Stock Titan", "published_at": "2026-04-18T13:39:54", "published_display": "18 Apr 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director details RSUs, options and warrants in Form 3/A", "summary": "Apollomics Inc. Director Hong-Jung Chen filed an amended initial ownership report (Form 3/A) detailing their current equity holdings in the company. The filing indicates Chen holds 1,000 restricted stock units vesting in two tranches in 2026, options for 2,290 Class A Ordinary Sh", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-5c1ce502288e.html", "source_name": "Stock Titan", "published_at": "2026-04-17T23:09:55", "published_display": "17 Apr 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director discloses 1,000 restricted stock units award", "summary": "Apollomics Inc. director CHU YI-AN has reported an award of 1,000 restricted stock units (RSUs) in an amended Form 3/A filing. Each RSU represents a contingent right to receive one Class A Ordinary Share with a zero exercise price. The RSUs are scheduled to vest in two equal tran", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-d56fa7dc6770.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director Huang Ya-Chi details RSU vesting and share holdings", "summary": "Apollomics Inc. director Huang Ya-Chi has reported their equity holdings in the company, including 1,500 restricted stock units (RSUs) and 500 Class A Ordinary Shares. The RSUs are set to vest in three equal tranches throughout 2026, with an exercise price of $0.0000 per share. T", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-4a700255d807.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CFO details 20,000 RSUs and 15,900 shares in Form 3/A", "summary": "Apollomics Inc.'s Chief Financial Officer, LIN PETER KUAN-HOW, filed an amended Form 3 detailing his equity holdings. The filing indicates he holds restricted stock units (RSUs) representing 20,000 Class A Ordinary Shares, which will vest in two equal tranches on June 15, 2026, a", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-96c45998823f.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director Jan Chen-Huan reports 1,000 RSUs and 1,000 shares", "summary": "Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report (Form 3/A) indicating holdings of 1,000 Restricted Stock Units (RSUs) and 1,000 Class A Ordinary Shares. The RSUs are set to vest in two equal installments of 500 shares each on June 15, 2026, and Septem", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-8ea2fc097b94.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) COO Yi-Kuei Chen discloses 5.3% ownership stake in latest filing", "summary": "Apollomics Inc.'s Chief Operating Officer, Yi-Kuei (Alex) Chen, has reported a beneficial ownership stake of approximately 5.3% in the company's Class A ordinary shares. This ownership, totaling 115,171 shares, includes direct holdings, shares held through Maxpro Investment Co., ", "url": "https://www.stocktitan.net/sec-filings/APLM/schedule-13d-apollomics-inc-major-shareholder-acquisition-5-fcd1293f9c4b.html", "source_name": "Stock Titan", "published_at": "2026-04-09T10:39:04", "published_display": "09 Apr 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yi-Kuei Chen Discloses Investment at Apollomics Inc. with 5.3% Stake", "summary": "Yi-Kuei (Alex) Chen, COO and director of Apollomics Inc., has disclosed a 5.3% beneficial stake in the company's Class A ordinary shares. This investment stems from vested and upcoming RSU grants and warrants, and Chen holds the shares for investment purposes, with no current pla", "url": "https://www.tradingview.com/news/tradingview:da582cda3e1b7:0-yi-kuei-chen-discloses-investment-at-apollomics-inc-with-5-3-stake/", "source_name": "TradingView", "published_at": "2026-04-08T22:39:33", "published_display": "08 Apr 2026 22:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) chair reports 41.8% stake and $2M convertible bridge loan", "summary": "Apollomics Inc. (APLM) chairman and CEO, Hung\u2011Wen (Howard) Chen, along with his entity King Regent Management Limited, now beneficially owns 41.8% of the company's Class A ordinary shares. Chen also provided Apollomics with an unsecured $2 million convertible promissory note as a", "url": "https://www.stocktitan.net/sec-filings/APLM/schedule-13d-a-apollomics-inc-amended-major-shareholder-report-126403a0e68b.html", "source_name": "Stock Titan", "published_at": "2026-04-06T17:39:55", "published_display": "06 Apr 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. Announces $2.0 Million Bridge Financing", "summary": "Apollomics Inc. announced a $2.0 million unsecured Convertible Promissory Note with its Chairman and CEO, Mr. Hung-Wen (Howard) Chen, on March 30, 2026. The proceeds will fund clinical development and general operations. The note bears 0% interest and will convert into equity upo", "url": "https://www.sahmcapital.com/news/content/apollomics-inc-announces-20-million-bridge-financing-2026-04-01", "source_name": "Sahm", "published_at": "2026-04-05T23:09:04", "published_display": "05 Apr 2026 23:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO funds Apollomics (Nasdaq: APLM) with $2M zero-interest convertible note", "summary": "Apollomics Inc. (Nasdaq: APLM) has secured a $2 million zero-interest convertible promissory note from its Chairman and CEO, Hung-Wen Chen, for working capital and clinical development. This related-party transaction, approved by the independent Audit Committee and Board with Che", "url": "https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a72186ed886.html", "source_name": "Stock Titan", "published_at": "2026-04-01T21:39:44", "published_display": "01 Apr 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "APLMW SEC Filings - APOLLOMICS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Apollomics Inc. (APLMW) SEC filings, including annual, quarterly, and material event reports, with AI-generated summaries for easier review. It details the company's focus on oncology therapies, financial situation, governance change", "url": "https://www.stocktitan.net/sec-filings/APLMW/page-2.html", "source_name": "Stock Titan", "published_at": "2026-03-20T02:39:22", "published_display": "20 Mar 2026 02:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director in Apollomics (APLM) reports 2,000 restricted stock units on Form 3", "summary": "Apollomics Inc. Director TSAI HSIEN-SHU has reported an initial holding of 2,000 restricted stock units (RSUs) on a Form 3 SEC filing. These RSUs are tied to Class A Ordinary Shares and vest over time, with 500 shares vesting upon grant on February 9, 2026, and subsequent 500-sha", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-apollomics-inc-initial-statement-of-beneficial-ownership-00838efc21ca.html", "source_name": "Stock Titan", "published_at": "2026-03-18T22:38:33", "published_display": "18 Mar 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Announces Settlement of Cayman Litigation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPOTd1UWFPMS1rN3MyWnc3anhwbnZiUmF2ekVCSDl3eUZ4MjJOUlQ2SE9MelpURTJsTVJMSEw0elJ1SGVaYVo4SWxiVmRZQmZyWS13cExOaUxjNGItR2lsWldwYjhZZ3FaelN0LUFaWWlCcW5KYTRCalRxTVZ4Y1R0eWNyeDdfamgwajY1bi11MTBkSFN1QVAyeGVrWU9tWV9QMHVXOEwzYw?oc=5", "source_name": "Sahm", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOTXRYQndyTGZRdXlEWFJ0VmtEbXlkNmN0T1RBZW94MkppSGFFaEtQZk04SHVqSEd2ZUVteFNxb2dRVHZ3STFXSWx5QmVQOEp6ZzJGaEZ3eTU0TTMwUzlqWmdubERBX0dxX2ZORXAxek5abDlrMGJBUXgzUi1wdFhadjNMUXlfMzFvVGFiRjhGWm5FSXZtbnc?oc=5", "source_name": "Market source", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics, Inc. Company Operational Continuity Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNVFQ5TjJUUDBVdV82cThTZUt2RjY1WE5aZDBfUFM2Vmh3REpZa0tiN0lWcnFXWnhyWWFFQlQzdEhDV0p1Y01SbHI3NnJnOGh2eEFrNW5PTDQ2cHhYT3p6d2d0RVlZay1Cd0ZmUENORVI4THF6OEdPS2pyRlh3Q2NDVU41XzdKMTBVZW9heXNnekVlc0daWmc?oc=5", "source_name": "Market source", "published_at": "2025-10-13T07:00:00+00:00", "published_display": "13 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE80Z0pWcW5xOUs1amJ6YVNkMURwWTdPWmVvTGE1RmJmU3ZDRUs4enpuTTA3MUdraU1TbHZWdDhaRHVTNWhWVS0tYkZjNmpXaHg1WFZDb2ZVSmR5aENFcjY2aTlYTF80dw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:17:20+00:00", "published_display": "11 May 2024 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics, Inc. (APLM) stock price, news, quote and history", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE8xZU1sYzE4UjFMclJuSXVOWDg3LTdqb0dZM1RFZnY4SDlielhnRUdGclBCUEdYYXJSeXR0UHgtaWNfaGRIWTZzcDdRTng2ZzJnc0E?oc=5", "source_name": "Market source", "published_at": "2023-08-19T03:21:01+00:00", "published_display": "19 Aug 2023 03:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APLM Stock Price and Chart \u2014 NASDAQ:APLM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBMeUt3YnhRQ1Vya3hlTm1oaXFOa084M2REdzZuTDNLbGh6MjhrUGd5MlFSZ0RkdjkyQ254RWRoWkNxYkZFLW9uWVBvRWx5R2NKc3ZVckFHN0R6bGZG?oc=5", "source_name": "TradingView", "published_at": "2023-05-24T07:00:00+00:00", "published_display": "24 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Apollomics Inc. (APLM) appoints Hung-Hsien Yen to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQc1pxd2x4cnBvN2NveURRbmF4LTRLNGp1QjRJZ0xKZUVfdDc1aTJ5c0VyQzRvVFZzUnYxeUJfMmNFZHVTNmxBbHY4Y25jRlRtUnNZWkVTZkxiSl9sSEROeFpSUGswdHVnQlVMU3d2d2l6cUVrMDJHWUsyUWVYYkk1a05BSi1VblhfUUVBMTk3OWRFa0QwT3VoWGZ1cDRJemtrWndERGFOVURjcTEyYS1z?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T19:13:53+00:00", "published_display": "21 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Plunges Over 21%: Key Support Levels Tested Amid Heavy Selling - IV Rank", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNWVF0bWFQaERNODBJY3Fvd29pRmhmbXdiLUlBOTNKOTNNR1dXSnJxQ0p4TFlQNGxYYVJGNUp4TzZ5a0Rjd0QtdXJBQlFjNjBtSTNURW1ERHpyRUlnUFJFWEtCV1FqWmNRbmVPV0wxdHpldDdOeUpBMkFWTFBiTVBUelIxc3B0OHo4SkFFN1hyX2NJTmhjeXB1U0lzYjRRWXRZVXFaakdsOXFzWFU4aVBmc0JtNkdrZjNOay1XbDlsZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-17T19:31:10+00:00", "published_display": "17 Jul 2026 19:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (Nasdaq: APLM) restores compliance with Nasdaq $35M MVLS rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOeHZrc1g1XzR5YXRaUmMxVzRORjJOZ0d2blM2MW8ydlpiUXV2Rlh3eEE4TnljVjN3b0ROWFZ2cW1MWGlfWndwcFZtN1VEUkk2a1NTd0VoU2l5VXFYM1VMYUlidUlSZjlQT2hUWEZmN2tFN2d6OTVFbmlVS1h2UE13UjJkWGZLMDFDX3hvb2prVXR0UmtQT3hRNDNZNUFSbk1uTXdyZGNnTEFIUkhla3Vj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Regains Full Compliance with Nasdaq Listing Requirements", "summary": "Apollomics Inc., a biopharmaceutical company, announced it has regained full compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement. The company had previously received notice of non-compliance but has since maintained the required $35 million MVLS for 10 c", "url": "https://www.sahmcapital.com/news/content/apollomics-regains-full-compliance-with-nasdaq-listing-requirements-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T01:12:20", "published_display": "14 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq restores Apollomics listing compliance after MVLS climbs back to $35M", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOTzJGbDBBZ2x2eHZMQ3I4WC1sdm82T2lDelR3Q01HWXhVX1Fna1lVd3ZKMWRJZnVkX1NJVGZuSUk0VG9xTnhCU2QxWDJYeG1HMVhqNDI0SVpoZ1lrSUt5NFc3bmwyNzJzNHRKUGZveTBSVHFnd3pQcUpxdGRNMFpiRGg5ZElJNkVZYy1tOFh3WVpobFNEbTNJV19NREhHV2JtRHpIUXhaNFQwMDZta2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Plunges Over 10%, Testing Key Support at $18.14 - Dynamic Hedging", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNT1B6LVhwc25vamdlbG9zeDZzTVc3VXU1bVdLQjdYbFVjbzVBUWJmZzRESktwcVhWSmpqSThrMmxya2hmeXpLTlctMjVsdFE3N0Q5RnF6bFZ0QkttX0xyOE9ESVQ1dUNua3JtQUJQZ3JtRzhlM3ZrSk15c29XbE5sRmNoYXZtX2JnVGVCRGJaa0tmZ05PSVVibE5mQ2FzcjdEWnZXSQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. Class A Actuals & Estimates (BOATS:APLM)", "summary": "This article provides an overview of Apollomics Inc. (APLM) stock, including its ticker information, analyst forecasts, historical price performance, and financial data. It explains where to find financial reports, its next earnings date, net income, dividend policy, and employee", "url": "https://www.tradingview.com/symbols/BOATS-APLM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:26", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Receives Nasdaq Deficiency Notice Over Market Value Requirement", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/apollomics-receives-nasdaq-deficiency-notice-205209617.html", "source_name": "MT Newswires", "published_at": "2026-06-24T20:52:09+00:00", "published_display": "24 Jun 2026 20:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/apollomics-receives-nasdaq-deficiency-notice-201500175.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T20:15:00+00:00", "published_display": "24 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Receives Nasdaq Deficiency Notice Regarding", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxNa0llMjlOd0VFMGN3cWIycUVnSEJfeTg1OTk1NkZhQS1UNDVHdVVSZ2dJZlN2c3NJTURxMVFyeTNuRjN6SFMxSVhfdTRxWG9oemNhWjlsTHNkM3RoQTBQb1dUc09rQWtUVFZHZEpjYUd5RG16T1l6UTZQNkJvUXhzaHdxQ0E3R2FFUzhYY1EtTDloOGNYV2ZXaXVNblppRWdHbWp6VmFLNHpRdXRHME5xR0Y2bktXeDFwWFloTV83X2lucnlmMkV1T1pJSnhnSVBFYTNZUnd4VjZMbW1vVzVCcGpDSl9TNXdjY2wwUU9LWHdVZ1dPRkFKUVduOVk0NHowWFBYcVNxUzljb0dvUng1WDZmelZ6SkkxS01NQ2VTbmZuVllzLTdDWm1DNmlDQ0FhSFZKcg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq flags Apollomics (NASDAQ: APLM) as MVLS falls short and Launxp deal ends", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNZ1gwRHhSS0VmWXBET0NDT2wxUHZqbm5RU2NSSDdGcEw2X1k1eENFNXBPdmZ0Tll1c3ZXSTVoQVk4U0l6U0VnWU10TkZpZzVxTkFWM3U3b19vU1JFQlJkVFB0UGJ0ZnZJNmdXazZnOVFQSkZvVTlyMTdQZHRUbW1uLUtBaEdvQWhiUGpYTFhaWjNvZVQyQ3pzajJiMXh6aGhmVDgzaEM2TE96NGdhY3dz?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CFO RSU vesting triggers 3,588-share tax withholding", "summary": "Apollomics Inc. (APLM) CFO Peter Kuan-How Lin reported the vesting of 10,000 Restricted Stock Units (RSUs) on June 15, 2026, which converted into Class A Ordinary Shares. To cover tax obligations related to this vesting, 3,588 shares were disposed of through a tax-withholding mec", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-87654a8ca2e9.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:39:55", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CEO Hung-Wen Chen gains 5,000 shares as RSUs vest", "summary": "Apollomics Inc. CEO Hung-Wen Chen acquired 5,000 Class A Ordinary Shares due to the vesting of Restricted Stock Units on June 15, 2026. This transaction was not an open-market trade but an equity compensation event, with shares valued at $0.00 each. Following this, Chen directly ", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-8fbeeddff6dc.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:10:22", "published_display": "17 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director receives 500 shares from RSU vesting", "summary": "Apollomics Inc. director Tsai Hsien-Shu increased his direct equity stake by 500 Class A Ordinary Shares due to the vesting of 500 Restricted Stock Units (RSUs) on June 15, 2026. This transaction is part of a pre-scheduled equity compensation plan, with additional RSUs set to ves", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-98b503af032b.html", "source_name": "Stock Titan", "published_at": "2026-06-17T02:05:22", "published_display": "17 Jun 2026 02:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Apollomics Inc. Insider Trading Activity", "summary": "Apollomics Inc.'s COO, Yi-Kuei Chen, reported insider trading activity involving restricted stock units (RSUs). On June 15, 2026, he exercised 5,000 RSUs, receiving Class A Ordinary Shares, increasing his direct holdings to 15,000 shares. He also has an indirect interest in over ", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-2d2ac5bdf8d7.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director vests 500 RSUs into Class A shares", "summary": "Apollomics Inc. director Hong-Jung Chen converted 500 Restricted Stock Units (RSUs) into 500 Class A Ordinary Shares on June 15, 2026, at an exercise price of $0.00 per share. This transaction increased his direct holdings to 3,620 Class A Ordinary Shares. This vesting event was ", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-14b5ba6469a8.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Apollomics (APLM) gains 500 shares from vested RSUs", "summary": "Apollomics Inc. director Jan Chen-Huan reported a routine equity compensation event where 500 Restricted Stock Units (RSUs) vested into 500 Class A Ordinary Shares on June 15, 2026. Following this transaction, Chen-Huan directly holds 1,500 Class A Ordinary Shares and 500 RSUs. T", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-2fba81a1dda4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director acquires 500 shares through RSU vesting", "summary": "Apollomics Inc. director, CHU YI-AN, acquired 500 Class A Ordinary Shares through the vesting and exercise of Restricted Stock Units (RSUs) at a price of $0.00 per share. This transaction, which occurred on June 15, 2026, increased CHU YI-AN's direct holdings to 1,500 Class A Ord", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-129aaeefb09c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:10:22", "published_display": "16 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Faces Pressure Amid Recent Decline \u2013 Key Levels to Watch - PCR Extreme", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPenhVS2FLb0dteWdZWDFsUE1WR2VNb3I3V2NHMXVVNWFjUnNWT01vcWlFaGt5SV85ekM4cmV1T3RSbXZ1ZERodnZMamNkMWhDVS1BOGJrZUExblFLbWxBMlcxaGxLTlRCUmQzcjJoV1hVcFFEd2I5aXhDa29KbWZYTFR6dTZYd2dvdHlrVk55R1dXUEJLRmRKQlVRX3dCOXo5dlBjMFJqS0RQeWZVdVJ1bFpBSjZwVTZ6NExF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Edges Higher as Stock Tests Resistance Near $14.86 - Pre-Earnings Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOeFNNZVR0NHNRa2dlTGdfZ3pQQmpBekoycEVmcjZ6LUxxU0d2ZWIzN0J3NnhQYUYyZGt1cl9JY3BQam5YS1pEZlhDR2JCdDI1MVlEN3QxWGs3MjZ6Yzc5WnZYenV5TENnSE8wSWpLbnRNa0NjUElXTXhqb0pGckM4dTJQWWFLd3I1dWFQRG5keWVlUllHbnNNSkUxaTMzOXdLejI5NG0ySEJfMkJSSEJ0ZkVB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) Holds Steady Near Support Level as Consolidation Persists - ETF Premium Discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNU2sxRnpVWXVfVUs3RWcxeUh5UFBxMHJTbXZtX0Z1aHk5ZGJDQkxWZzNQc3FIbHFTT3dSWGJ3bFZHaVJjOFJfcW9LU3ZEa0ZwbVRHWDQzN3lycC1WNWo4MmpQSTBiNVRZM2FjTy1POU9IamNLd1h4Qmc3T0dOMW82R3A0NDAwWmNfNHhqVFpNVnBTRWhodnRrNWx1aWFDU1o0Zm5Nd3dqd3JNazgzTVNtenFqWkJNLUpwMGVGdnF3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (Nasdaq:APLM) - Stock Analysis", "summary": "Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on oncology therapies, with a market capitalization of US$32.9 million. The company faces significant risks including negative shareholder equity, substantial share dilution, and volatile share p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aplm/apollomics", "source_name": "Simply Wall Street", "published_at": "2026-05-19T14:08:54", "published_display": "19 May 2026 14:08", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. (APLM) files F-3/A to register 279,775 Class A shares", "summary": "Apollomics Inc. has filed an F-3/A amendment to register 279,775 Class A ordinary shares for resale by existing securityholders who acquired them through PIPE subscription agreements. This registration is to satisfy certain registration rights, and Apollomics will not receive any", "url": "https://www.stocktitan.net/sec-filings/APLM/f-3-a-apollomics-inc-amended-foreign-issuer-shelf-registration-36fec23c9164.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:39:09", "published_display": "15 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APLMW | Apollomics Inc. Warrant Insider Trading", "summary": "This article provides an overview of Apollomics Inc. Warrant (APLMW) with a focus on potential insider trading activity, institutional holdings, and other financial data. It notes that there is no recent insider trading data or Congress trading data for this ticker. The piece als", "url": "https://www.quiverquant.com/stock/APLMW/insiders/", "source_name": "Quiver Quantitative", "published_at": "2026-05-02T20:39:51", "published_display": "02 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress", "summary": "Apollomics Inc. announced its full-year 2025 financial results, highlighting a strategic turnaround and significant progress in its clinical pipeline. The company is actively advancing vebreltinib, a c-MET inhibitor, with ongoing Phase 2 studies and plans for an IND submission fo", "url": "https://www.manilatimes.net/2026/04/27/tmt-newswire/globenewswire/apollomics-reports-full-year-2025-financial-results-and-provides-clinical-updates-and-business-progress/2329261", "source_name": "The Manila Times", "published_at": "2026-04-30T21:09:43", "published_display": "30 Apr 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Over 282 subjects enrolled as Apollomics targets 2027 U.S. filing", "summary": "Apollomics (Nasdaq: APLM) reported full-year 2025 financial results, with revenue reaching $8.5 million and net loss narrowing to $10.9 million. The company is advancing the global development of its lead oncology asset, vebreltinib (APL-101), with over 282 subjects enrolled in t", "url": "https://www.stocktitan.net/news/APLM/apollomics-reports-full-year-2025-financial-results-and-provides-5ee6bul16siu.html", "source_name": "Stock Titan", "published_at": "2026-04-30T02:39:19", "published_display": "30 Apr 2026 02:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APLM SEC Filings - APOLLOMICS INC 10-K, 10-Q, 8-K Forms", "summary": "This page on Stock Titan provides a comprehensive resource for Apollomics Inc. (APLM) SEC filings, including annual reports (10-K, 20-F), quarterly earnings (10-Q), material events (8-K, 6-K), and insider trading forms. It offers direct access to regulatory disclosures as Apollom", "url": "https://www.stocktitan.net/sec-filings/APLM/page-3.html", "source_name": "Stock Titan", "published_at": "2026-04-24T18:39:28", "published_display": "24 Apr 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CFO has shares withheld for RSU tax obligations", "summary": "Apollomics Inc.'s Chief Financial Officer, Peter Kuan-How Lin, had 3,582 Class A Ordinary Shares withheld to cover tax obligations at $15.85 per share upon the vesting of restricted stock units (RSUs). This was a routine tax-withholding event, not an open-market sale. Following t", "url": "https://www.stocktitan.net/sec-filings/APLM/form-4-apollomics-inc-insider-trading-activity-dad9b6707276.html", "source_name": "Stock Titan", "published_at": "2026-04-18T13:39:54", "published_display": "18 Apr 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director details RSUs, options and warrants in Form 3/A", "summary": "Apollomics Inc. Director Hong-Jung Chen filed an amended initial ownership report (Form 3/A) detailing their current equity holdings in the company. The filing indicates Chen holds 1,000 restricted stock units vesting in two tranches in 2026, options for 2,290 Class A Ordinary Sh", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-5c1ce502288e.html", "source_name": "Stock Titan", "published_at": "2026-04-17T23:09:55", "published_display": "17 Apr 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director discloses 1,000 restricted stock units award", "summary": "Apollomics Inc. director CHU YI-AN has reported an award of 1,000 restricted stock units (RSUs) in an amended Form 3/A filing. Each RSU represents a contingent right to receive one Class A Ordinary Share with a zero exercise price. The RSUs are scheduled to vest in two equal tran", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-d56fa7dc6770.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director Huang Ya-Chi details RSU vesting and share holdings", "summary": "Apollomics Inc. director Huang Ya-Chi has reported their equity holdings in the company, including 1,500 restricted stock units (RSUs) and 500 Class A Ordinary Shares. The RSUs are set to vest in three equal tranches throughout 2026, with an exercise price of $0.0000 per share. T", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-4a700255d807.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) CFO details 20,000 RSUs and 15,900 shares in Form 3/A", "summary": "Apollomics Inc.'s Chief Financial Officer, LIN PETER KUAN-HOW, filed an amended Form 3 detailing his equity holdings. The filing indicates he holds restricted stock units (RSUs) representing 20,000 Class A Ordinary Shares, which will vest in two equal tranches on June 15, 2026, a", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-96c45998823f.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) director Jan Chen-Huan reports 1,000 RSUs and 1,000 shares", "summary": "Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report (Form 3/A) indicating holdings of 1,000 Restricted Stock Units (RSUs) and 1,000 Class A Ordinary Shares. The RSUs are set to vest in two equal installments of 500 shares each on June 15, 2026, and Septem", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-a-apollomics-inc-amended-initial-statement-of-beneficial-owner-8ea2fc097b94.html", "source_name": "Stock Titan", "published_at": "2026-04-15T00:09:33", "published_display": "15 Apr 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) COO Yi-Kuei Chen discloses 5.3% ownership stake in latest filing", "summary": "Apollomics Inc.'s Chief Operating Officer, Yi-Kuei (Alex) Chen, has reported a beneficial ownership stake of approximately 5.3% in the company's Class A ordinary shares. This ownership, totaling 115,171 shares, includes direct holdings, shares held through Maxpro Investment Co., ", "url": "https://www.stocktitan.net/sec-filings/APLM/schedule-13d-apollomics-inc-major-shareholder-acquisition-5-fcd1293f9c4b.html", "source_name": "Stock Titan", "published_at": "2026-04-09T10:39:04", "published_display": "09 Apr 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yi-Kuei Chen Discloses Investment at Apollomics Inc. with 5.3% Stake", "summary": "Yi-Kuei (Alex) Chen, COO and director of Apollomics Inc., has disclosed a 5.3% beneficial stake in the company's Class A ordinary shares. This investment stems from vested and upcoming RSU grants and warrants, and Chen holds the shares for investment purposes, with no current pla", "url": "https://www.tradingview.com/news/tradingview:da582cda3e1b7:0-yi-kuei-chen-discloses-investment-at-apollomics-inc-with-5-3-stake/", "source_name": "TradingView", "published_at": "2026-04-08T22:39:33", "published_display": "08 Apr 2026 22:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) chair reports 41.8% stake and $2M convertible bridge loan", "summary": "Apollomics Inc. (APLM) chairman and CEO, Hung\u2011Wen (Howard) Chen, along with his entity King Regent Management Limited, now beneficially owns 41.8% of the company's Class A ordinary shares. Chen also provided Apollomics with an unsecured $2 million convertible promissory note as a", "url": "https://www.stocktitan.net/sec-filings/APLM/schedule-13d-a-apollomics-inc-amended-major-shareholder-report-126403a0e68b.html", "source_name": "Stock Titan", "published_at": "2026-04-06T17:39:55", "published_display": "06 Apr 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Inc. Announces $2.0 Million Bridge Financing", "summary": "Apollomics Inc. announced a $2.0 million unsecured Convertible Promissory Note with its Chairman and CEO, Mr. Hung-Wen (Howard) Chen, on March 30, 2026. The proceeds will fund clinical development and general operations. The note bears 0% interest and will convert into equity upo", "url": "https://www.sahmcapital.com/news/content/apollomics-inc-announces-20-million-bridge-financing-2026-04-01", "source_name": "Sahm", "published_at": "2026-04-05T23:09:04", "published_display": "05 Apr 2026 23:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO funds Apollomics (Nasdaq: APLM) with $2M zero-interest convertible note", "summary": "Apollomics Inc. (Nasdaq: APLM) has secured a $2 million zero-interest convertible promissory note from its Chairman and CEO, Hung-Wen Chen, for working capital and clinical development. This related-party transaction, approved by the independent Audit Committee and Board with Che", "url": "https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a72186ed886.html", "source_name": "Stock Titan", "published_at": "2026-04-01T21:39:44", "published_display": "01 Apr 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APLMW SEC Filings - APOLLOMICS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Apollomics Inc. (APLMW) SEC filings, including annual, quarterly, and material event reports, with AI-generated summaries for easier review. It details the company's focus on oncology therapies, financial situation, governance change", "url": "https://www.stocktitan.net/sec-filings/APLMW/page-2.html", "source_name": "Stock Titan", "published_at": "2026-03-20T02:39:22", "published_display": "20 Mar 2026 02:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director in Apollomics (APLM) reports 2,000 restricted stock units on Form 3", "summary": "Apollomics Inc. Director TSAI HSIEN-SHU has reported an initial holding of 2,000 restricted stock units (RSUs) on a Form 3 SEC filing. These RSUs are tied to Class A Ordinary Shares and vest over time, with 500 shares vesting upon grant on February 9, 2026, and subsequent 500-sha", "url": "https://www.stocktitan.net/sec-filings/APLM/form-3-apollomics-inc-initial-statement-of-beneficial-ownership-00838efc21ca.html", "source_name": "Stock Titan", "published_at": "2026-03-18T22:38:33", "published_display": "18 Mar 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Announces Settlement of Cayman Litigation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPOTd1UWFPMS1rN3MyWnc3anhwbnZiUmF2ekVCSDl3eUZ4MjJOUlQ2SE9MelpURTJsTVJMSEw0elJ1SGVaYVo4SWxiVmRZQmZyWS13cExOaUxjNGItR2lsWldwYjhZZ3FaelN0LUFaWWlCcW5KYTRCalRxTVZ4Y1R0eWNyeDdfamgwajY1bi11MTBkSFN1QVAyeGVrWU9tWV9QMHVXOEwzYw?oc=5", "source_name": "Sahm", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOTXRYQndyTGZRdXlEWFJ0VmtEbXlkNmN0T1RBZW94MkppSGFFaEtQZk04SHVqSEd2ZUVteFNxb2dRVHZ3STFXSWx5QmVQOEp6ZzJGaEZ3eTU0TTMwUzlqWmdubERBX0dxX2ZORXAxek5abDlrMGJBUXgzUi1wdFhadjNMUXlfMzFvVGFiRjhGWm5FSXZtbnc?oc=5", "source_name": "Market source", "published_at": "2025-10-15T07:00:00+00:00", "published_display": "15 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics, Inc. Company Operational Continuity Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNVFQ5TjJUUDBVdV82cThTZUt2RjY1WE5aZDBfUFM2Vmh3REpZa0tiN0lWcnFXWnhyWWFFQlQzdEhDV0p1Y01SbHI3NnJnOGh2eEFrNW5PTDQ2cHhYT3p6d2d0RVlZay1Cd0ZmUENORVI4THF6OEdPS2pyRlh3Q2NDVU41XzdKMTBVZW9heXNnekVlc0daWmc?oc=5", "source_name": "Market source", "published_at": "2025-10-13T07:00:00+00:00", "published_display": "13 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics (APLM) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE80Z0pWcW5xOUs1amJ6YVNkMURwWTdPWmVvTGE1RmJmU3ZDRUs4enpuTTA3MUdraU1TbHZWdDhaRHVTNWhWVS0tYkZjNmpXaHg1WFZDb2ZVSmR5aENFcjY2aTlYTF80dw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:17:20+00:00", "published_display": "11 May 2024 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Apollomics, Inc. (APLM) stock price, news, quote and history", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE8xZU1sYzE4UjFMclJuSXVOWDg3LTdqb0dZM1RFZnY4SDlielhnRUdGclBCUEdYYXJSeXR0UHgtaWNfaGRIWTZzcDdRTng2ZzJnc0E?oc=5", "source_name": "Market source", "published_at": "2023-08-19T03:21:01+00:00", "published_display": "19 Aug 2023 03:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APLM Stock Price and Chart \u2014 NASDAQ:APLM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBMeUt3YnhRQ1Vya3hlTm1oaXFOa084M2REdzZuTDNLbGh6MjhrUGd5MlFSZ0RkdjkyQ254RWRoWkNxYkZFLW9uWVBvRWx5R2NKc3ZVckFHN0R6bGZG?oc=5", "source_name": "TradingView", "published_at": "2023-05-24T07:00:00+00:00", "published_display": "24 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 55, "sentiment_summary": {"positive": 7, "negative": 5, "neutral": 43, "score": 51, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 18.52, "latest_week": "2026-07-17", "one_week_move": -2.3, "four_week_move": 5.8, "twelve_week_move": 39.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.048281, "market_dynamics_buy_signal": false, "relative_strength": 3.778217, "fair_value_gap": -67.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.4126, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, +5.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 25}, {"label": "Market source", "count": 9}, {"label": "dars.gov.et", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "MT Newswires", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 5}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.3% over one week, +5.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Apollomics Inc. (APLM) appoints Hung-Hsien Yen to board"}], "updated_at": "2026-07-24T11:47:03.210785+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}